Table 1 Univariate analysis for factor affecting prognosis.

	N	OS rate (%)			X²	P	PFS rate (%)			X²	P
	N	1 year	2 year	3 year	X²	P	1 year	2 year	3 year	X²	P
Sex					3.067	0.080				0.031	0.860
Male	58	84.1	57.1	48.8			60.1	29.2	27.1
Female	21	90.2	78.2	78.2			70.7	32.7	21.8
Age (Year)					0.032	0.857				0.179	0.672
≤ 66	41	82.9	62.6	54.8			63.4	32.3	29.6
> 66	38	89.3	61.3	57.7			62.2	27.6	22.1
Tumor location					3.036	0.219				0.732	0.693
Cervical/upper thoracic	24	82.9	68.5	68.5			70.3	37.5	37.5
Middle thoracic	37	86.3	67.0	55.5			67.2	26.2	18.3
Lower thoracic	18	88.1	44.1	37.8			44.4	27.8	27.8
ECOG score					3.492	0.062				1.997	0.158
0–1	54	86.4	68.4	68.4			69.7	35.6	29.5
2	25	84.0	52.0	38.5			48.0	20.0	20.0
Histologic grade					0.685	0.408				0.251	0.616
Poorly differentiated	20	95.0	66.6	66.6			50.0	33.3	26.7
Moderate/Highly Differentiated	59	82.5	60.7	52.9			67.3	29.5	26.5
Clinical stage					6.590	0.010				9.360	0.002
II + III	50	89.8	70.9	68.4			79.9	37.6	32.1
IV	29	78.9	47.4	35.9			33.0	17.6	17.6
Number of immune cycles (cycles)					8.408	0.004				2.765	0.096
≤ 6	44	74.4	45.6	45.6			54.0	26.9	16.0
≥ 7	35	100	83.3	70.5			73.7	33.9	33.9
Chemotherapy cycles					0.001	0.974				0.025	0.875
≤ 3	39	78.9	61.1	61.1			66.3	32.4	27.8
≥ 4	40	92.4	63.3	51.6			59.5	28.0	24.9
Radiation coverage					7.087	0.008				0.262	0.609
All lesion	56	87.2	70.2	65.8			67.5	30.9	25.5
Partial lesion	23	82.1	43.5	33.8			51.0	27.8	27.8
ICIs sequence					10.345	0.001				7.045	0.008
Sequential	50	98.0	76.2	66.3			69.4	42.4	36.9
Concurrent	29	65.2	39.8	39.8			51.3	11.0	11.0
Short term efficacy					7.762	0.005				4.449	0.035
CR + PR	65	87.4	69.7	62.3			65.8	33.7	29.5
SD + PD	14	77.9	26.3	26.3			49.0	12.2	12.2

Complete response (CR), partial response (PR), immune checkpoint inhibitors (ICIs)

Quick links

Search